Key points
CAC score is a low-dose non-contrast cardiac CT that directly shows plaque already accumulated in the coronary arteries; the table shows where this snapshot helps and what studies have shown.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Heart attack risk in an adult without symptoms | directly sees plaque in your own arteries rather than an averaged population probability; reclassifies patients more accurately than an ASCVD score based on lipids alone | coronary calcium predicted coronary events in four racial and ethnic groups (Detrano, NEJM 2008); adding CAC refined coronary heart disease risk classification (Polonsky, JAMA 2010) |
| Score 0 — "power of zero" | the strongest negative predictor: a justified opportunity to work through prevention, no default statin if overall risk is low and there is no familial hypercholesterolemia | in people older than 45 years, 10-year myocardial infarction risk below 1% |
| A "50/50" statin decision (age 40–75 years, ASCVD risk 5–20% over 10 years), early myocardial infarction in the family, menopause, metabolic syndrome, Lp(a) > 50 mg/dL | with moderate lipid risk, CAC = 0 gives a justified reason to defer a statin, CAC > 100 a reason to start; with early myocardial infarction in the family and Lp(a) > 50 mg/dL, it shows how much of the risk has already been realized; the main indication follows the 2019 ACC/AHA guidelines | — |
| CAC 100–399 and ≥400 | grounds for a statin with an LDL target <1.8 mmol/L (70 mg/dL); at ≥300 — statin + ezetimibe ± a PCSK9 inhibitor, at ≥400 — also functional testing | in MESA, CAC > 300 carried a 9.67-fold higher risk of a coronary event than CAC 0 over a median of 3.8 years (Detrano, NEJM 2008) |
| High CAC and LDL above target on a statin plus ezetimibe | PCSK9 inhibitors lower LDL by 50–60% beyond the maximum statin dose and Lp(a) by 25–30% | FOURIER, 27,564 patients with established cardiovascular disease: evolocumab on top of a statin reduced the composite endpoint by 15% over 2.2 years, LDL fell from 2.4 to 0.8 mmol/L (from 92 to 30 mg/dL) (PMID 28304224); ODYSSEY OUTCOMES, 18,924 patients after acute coronary syndrome: alirocumab reduced the risk of major cardiovascular events by 15% |
How it helps
A test that sees plaque instead of calculating risk
When people talk about "assessing myocardial infarction risk," they usually mean risk scores — ASCVD, SCORE2, Framingham. These scores combine age, sex, blood pressure, LDL, diabetes, and smoking, then output the probability of an event over 10 years. This is a useful tool, but it has a fundamental limitation: it does not see your own blood vessel. It averages the population.
CAC score (coronary artery calcium) is a low-dose non-contrast computed tomography scan of the chest that measures coronary artery calcification using the Agatston scale. It is direct visualization of atherosclerotic plaque, not a probability.
Key idea of the md_pereligyn protocol: LDL and ApoB tell us what pressure is pushing into the vessel wall. CAC shows what has already accumulated in the wall itself. These are two different snapshots — past damage (CAC) and future pressure (ApoB / Lp(a)) — and they are used together, not instead of each other.
After 10–20 years of elevated ApoB or hypertension, plaque calcifies. CT can see it. The ASCVD score cannot. That is why CAC can reclassify a patient — avoid a statin in someone who was "borderline" by risk score, or start aggressive therapy where the lipid panel looked reassuring.
What the Agatston score measures
The Agatston score sums the volume and density of calcified lesions across all coronary arteries. Calcification is a marker of mature atherosclerotic plaque.
The method has important characteristics:
- Low radiation dose — 0.5–1.5 mSv, roughly 2–8 months of natural background radiation (about 2.4 mSv per year on average).
- No contrast — no kidney burden, no allergic reactions.
- High reproducibility — interobserver variability <10%.
- 10–15-year prognosis — not a one-time snapshot, but a long-term predictor.
- Cost 100–250 USD in most countries — more accessible than angiography.
Agatston score categories
The score is divided into four clinically meaningful categories, each with its own strategy.
- Score 0 — Power of zero. No calcified plaque. This is the strongest negative predictor in people older than 45 years: 10-year myocardial infarction risk below 1%. Repeat in 5–7 years, especially with a family history.
- Score 1–99 — mild calcification. Atherosclerosis has started but is not yet mature. Intensify prevention — lifestyle, omega-3, ApoB and blood pressure control. A statin is not prescribed by default; the decision is individualized.
- Score 100–399 — moderate calcification. Equivalent to intermediate-high risk. Statin therapy is indicated for most patients, with aggressive LDL control to <1.8 mmol/L (70 mg/dL) and discussion of aspirin if there are no contraindications.
- Score ≥400 — high risk. Aggressive lipid-lowering (statin + ezetimibe ± PCSK9; discussed from CAC ≥300), blood pressure control, and discussion of functional testing (stress test, CT angiography). In MESA, CAC > 300 carried a 9.67-fold higher risk of a coronary event than CAC 0 over a median of 3.8 years (Detrano R, NEJM 2008, PMID 18367736).
In MESA, each doubling of CAC raised the risk of a major coronary event (myocardial infarction or coronary death) by 15–35% and of any coronary event by 18–39% (Detrano R, NEJM 2008, PMID 18367736).
| Score | Category | Action |
|---|---|---|
| 0 | no plaque | risk <1%, no default statin |
| 1–99 | mild | intensify prevention |
| 100–399 | moderate | statin, LDL <1.8 mmol/L (70 mg/dL); from 300 — statin+ezetimibe±PCSK9 |
| ≥400 | high | statin+ezetimibe±PCSK9 |
Who should have the test
CAC provides the most information not for everyone, but for a clearly defined subgroup — people in whom the statin decision is "50/50."
- Age 40–75 years + intermediate ASCVD risk (5–20% over 10 years) — to refine the statin decision. This is the main indication supported by the 2019 ACC/AHA guidelines.
- Family history of early myocardial infarction (father < 55 years, mother < 65 years) — regardless of lipid levels.
- Perimenopausal and postmenopausal women with borderline lipids — in women, the ASCVD score often underestimates risk.
- Patients who do not want to take a statin despite moderate lipid risk — CAC = 0 provides a justified reason to defer; CAC > 100 provides a reason to "start after all."
- Patients with metabolic syndrome, prediabetes, PCOS — for vascular age stratification.
- Lp(a) > 50 mg/dL — CAC helps show how much of the genetic risk has already been realized.
CAC together with other tests
CAC sees mature calcified plaque. Alongside it, physicians assess what calcium does not show:
- Lp(a) — a genetic risk factor that increases LDL atherogenicity and promotes aortic valve calcification. It is measured once as a blood test. More detail in the article Lp(a) — genetic cardiovascular risk factor.
- ApoB — the number of atherogenic particles in plasma. LDL shows cholesterol within these particles; ApoB shows their number. ApoB predicts risk more accurately, especially in metabolic syndrome.
- hsCRP — a marker of vascular inflammation and plaque instability. Plaque can be small but "hot."
- Endothelial dysfunction — an early stage of vascular injury that precedes plaque by 10–20 years. See Endothelium: foundation of vascular health.
Principle: CAC is a snapshot of past damage. ApoB and Lp(a) are a snapshot of future pressure. hsCRP is a snapshot of current inflammation. They are used together.
Holistic protocol for different CAC levels
1. CAC = 0
- Confirm that there are no other high-risk markers: Lp(a), family history, ApoB > 100 mg/dL, hsCRP > 2 mg/L.
- Support: Mediterranean / DASH diet, movement 150+ min/week, omega-3 index >8%, vitamin D 50–80 ng/mL, sleep control.
- Do not prescribe a statin by default if overall risk is low and there is no familial hypercholesterolemia.
- Repeat in 5–7 years (earlier if younger than 50 years).
2. CAC 1–99
- Intensify prevention: ApoB target <80 mg/dL, blood pressure <120/80, omega-3 index >8%, insulin sensitivity index (HOMA-IR <1.5).
- Nutraceuticals: omega-3 EPA+DHA 2 g/day, magnesium (glycinate) 400 mg, vitamin D3 + K2 (MK-7) 100–200 μg, CoQ10 100–200 mg, pomegranate extract 250–500 mg for the endothelium.
- Lifestyle: smoking cessation (absolute priority), 7–8 h of sleep, strength + aerobic training.
- Statin decision: individualized, based on the totality of factors. In some patients, it is reasonable to start a low-dose statin (rosuvastatin 5–10 mg).
- A statin is not decided by CAC alone: the decision includes an assessment of overall risk; in a patient with CAC 50 and ApoB 60 mg/dL plus an excellent lifestyle, the statin decision is individualized.
3. CAC 100–399
- Statin therapy for most: rosuvastatin 10–20 mg or atorvastatin 20–40 mg with a target ApoB <70 mg/dL / LDL <1.8 mmol/L (70 mg/dL). At CAC ≥300 — statin + ezetimibe ± a PCSK9 inhibitor, as in section 4.
- Blood pressure control to <130/80, ideally 120/80 when possible.
- HbA1c <5.7%, fasting insulin <8 μIU/mL.
- Aspirin 75–100 mg — discussed individually if bleeding risk is not increased.
- Full carotid artery evaluation (internal carotid artery ultrasound), functional stress test if symptomatic.
- Holistic support: omega-3 2–4 g/day, CoQ10 200 mg (especially on a statin), polyphenols (pomegranate, cocoa, EGCG), magnesium 400 mg.
4. CAC ≥ 400
- Aggressive lipid-lowering (from CAC ≥300): statin + ezetimibe; if ApoB does not reach the target <65 mg/dL — add a PCSK9 inhibitor (alirocumab, evolocumab).
- Stress test and/or CT angiography to identify a functionally significant stenotic zone.
- Cardiologist: lifelong follow-up, discussion of revascularization if ischemia is present.
- Control of all modifiable factors: smoking — complete cessation, blood pressure, glycemia, weight, sleep, stress.
- Holistic support: the same nutraceuticals as for CAC 100–399, plus emphasis on the endothelial protocol (L-arginine 3–6 g, citrulline 3 g, BH4 regeneration with polyphenols).
PCSK9 inhibitor dosing in patients with high CAC
The protocol for CAC ≥300 mentions PCSK9 inhibitors; their doses and evidence are below. Evolocumab and alirocumab are monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Blocking PCSK9 increases the density of LDL receptors on hepatocytes and lowers LDL cholesterol by 50–60% beyond what the maximum statin dose achieves.
Standard dosing regimens. Evolocumab (Repatha): 140 mg subcutaneously every 2 weeks or 420 mg once a month. Alirocumab (Praluent): 75 mg or 150 mg subcutaneously every 2 weeks. The 75 mg dose is the starting dose; if LDL lowering is insufficient after 4–8 weeks, titrate to 150 mg. Both drugs are self-injected into the thigh, abdomen, or upper arm.
Evidence. FOURIER (n = 27,564): patients with established cardiovascular disease who received evolocumab on top of a statin had a 15% reduction in the composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for angina, revascularization) over 2.2 years. LDL fell from 2.4 to 0.8 mmol/L (from 92 to 30 mg/dL) (PMID 28304224). ODYSSEY OUTCOMES (n = 18,924) showed the same for alirocumab: a 15% lower risk of major cardiovascular events in patients after acute coronary syndrome.
Who is a candidate with high CAC. The indication is determined not by the score itself but by statin resistance. Candidates: CAC ≥300 + LDL >1.8 mmol/L (70 mg/dL) on the maximum tolerated dose of a statin + ezetimibe; familial hypercholesterolemia with CAC >0 at any age; patients with statin-induced myopathy who cannot reach LDL targets. In patients with Lp(a) >50 mg/dL and CAC >100, PCSK9 inhibitors lower Lp(a) by 25–30% — an additional benefit that statins do not provide.
Tolerability. The main adverse effects are injection-site reactions (minimal) and nasopharyngitis. No serious metabolic or cognitive effects were recorded in FOURIER and EBBINGHAUS. The drugs do not affect liver function and do not require AST/ALT monitoring.
When to repeat
Changes accumulate slowly, so CAC does not need to be repeated every year: an informative interval is 3–5 years (1 year when selecting aggressive therapy).
- CAC > 400 in the recent past — repeating it every year is pointless unless the treatment plan is changing; the focus then is functional diagnostics and ApoB control.
Who does not need the test
- Age < 40 years without family history — calcification has not yet had time to develop, so the result may be falsely reassuring. ApoB and Lp(a) work better in younger people.
- Already established coronary artery disease, prior myocardial infarction, previous stenting/CABG — a statin is indicated regardless of the score, and the decision has already been made.
- End-stage systemic disease of any kind — the priority is different.
Who should see a doctor first
- Pregnancy — radiation exposure, an absolute contraindication.
- Women of reproductive age — discuss the test with a physician first.
- Do not ignore symptoms when CAC = 0 — typical angina requires evaluation regardless of the score. Score 0 does not exclude rupture of a young soft plaque.
- CAC = 0 with high ApoB or Lp(a) — do not stop prevention: this is still high risk.
When to seek care
- Age 40–75 years with intermediate ASCVD risk (5–20% over 10 years)
- Family history of coronary artery disease / myocardial infarction / stroke before age 60 years (men <55, women <65)
- Borderline lipids + uncertainty about a statin
- Metabolic syndrome, prediabetes, type 2 diabetes
- Lp(a) > 50 mg/dL (>125 nmol/L)
- hsCRP > 2 mg/L on repeated testing
- Desire for an objective assessment of vascular age
Bottom line
CAC score is the most accurate single screening test for cardiology risk in an asymptomatic adult. It does not replace the lipid panel and is not the same as "having the full workup," but it reclassifies patients more accurately than any risk score. Score 0 provides a justified opportunity to work through prevention; Score ≥300 justifies aggressive therapy.
The combination of CAC + ApoB + Lp(a) + hsCRP + omega-3 index gives the physician four different cross-sections of the same process: accumulated damage, current pressure, genetic background, and inflammation. This quartet is the basis of modern cardiovascular prevention, and it is exactly what the md_pereligyn protocol places above the ASCVD score.
I perform full vascular stratification (CAC, Lp(a), ApoB, omega-3 index, hsCRP, HOMA-IR) and create a personalized plan — which tests, in what order, and which holistic protocol fits your risk level; you can book a consultation.
Treat the vessel, not its complications.
Sources
- Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–1345. PMID 18367736
- Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010;303:1610–1616. PMID 20424251
Related articles: Endothelium: foundation of vascular health, Cholesterol without statins.
Source: CAC score: coronary artery calcium as the most accurate heart screening test — universum.earth. md_pereligyn — Перелыгин Владимир Игоревич.
